Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations

Oct 30 2019

• By Reed Miller

MT1910_Third Quarter_292136531_1200.jpg — • Source: shutterstock.com

Related Content

Manufacturers Support CMS’ New TAVR National Coverage Decision

Jun 24 2019

FDA Expands TAVR Indication To Low-Risk Patients

Aug 16 2019

Edwards’ Resilia Surgical Valve Proves Durability in COMMENCE Study

May 07 2019

Market Brief: PBV Systems Fastest-Growing Segment In Global Surgical Heart Valve Management Market

May 20 2019

Edwards Discontinues Centera TAVR Program As Sapien Sales Continue To Climb

Jul 24 2019

TCT 2019: One-Year PARTNER 3 Outcomes Show Better Quality Of Life With TAVR

Oct 03 2019

Edwards Lifesciences Buys CAS For $100M

Feb 12 2019

Harpoon Finds Its Whale: Edwards Spends Up To $250m For Beating-Heart Mitral Repair Option

Dec 12 2017

Related Companies

Edwards Lifesciences Corp.

Abbott

CAS Medical Systems, Inc.

Additional Topics

Commercial Sales & Earnings Clinical Trials Cardiovascular Cardiology Medical Device

More from Cardiology

More from Device Area

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window